Highlights Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-09 EDT			5-day change	1st Jan Change
0.3726 ^USD	-13.15%		-11.54%	-35.20%

05-09	Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-29	CI
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	01-22	CI
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID	01-02	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement	23-09-18	CI
Virios Therapeutics Shares Slump After Company Reports Q2 Loss	23-08-10	MT
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia	23-08-09	CI
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study	23-07-17	CI
Virios Therapeutics Regains Compliance With Nasdaq Listing Rule	23-05-26	MT
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
VIRIOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-14	AQ
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023	23-02-13	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Virios Therapeutics, Inc. Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia	22-09-19	CI
Virios Therapeutics, Inc. Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial	22-08-15	CI
Virios Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Highlights

Filters